VEON publishes audited financial statements for year ended 31 December 2022

Written by Customer Service on June 24, 2023. Posted in Public Companies.

VEON publishes audited financial statements for year ended 31 December 2022 Amsterdam, 25 June 2023 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides connectivity and online services (“VEON” or the “Company” or, together with its subsidiaries, the “Group”), today announces that it has published its Dutch Annual Report – 2022, including consolidated financial statements for the year ended 31 December 2022 prepared in accordance with International Financial Reporting Standards as adopted by the European Union and with Part 9 of Book 2 of the Dutch Civil Code (the “Consolidated Financial Statements). A copy of the Dutch Annual Report – 2022 can be found on the Reports and Results section of the Company’s website at https://www.veon.com/investors/reports-results/. The Consolidated Financial Statements...

Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials

Written by Customer Service on June 24, 2023. Posted in Public Companies.

After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs once-daily basal insulin glargine U100 in ONWARDS 11 In the ONWARDS 1 and 3 trials, more people achieved blood glucose targets without clinically significant or severe hypoglycaemia with once-weekly basal insulin icodec vs once-daily basal insulin comparators1,2 Insulin icodec has been submitted for regulatory review in the US, Canada, Europe, China, Australia, Switzerland and Brazil. First decisions are anticipated in H1 2024 Bagsværd, Denmark, Sunday 25 June 2023 – Novo Nordisk today announced data from the phase 3a ONWARDS 1 and 3 trials evaluating investigative once-weekly basal insulin...

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

Written by Customer Service on June 24, 2023. Posted in Public Companies.

– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in all-cause mortality – – Bempedoic acid is the first LDL-lowering therapy since statins to demonstrate cardiovascular risk reduction in a primary prevention population – – Of the patients included in the primary prevention population, nearly two-thirds were diabetic – – Results simultaneously published in the Journal of the American Medical Association (JAMA) – ANN ARBOR, Mich., June 24, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced the results from the pre-specified, primary prevention CLEAR Outcomes subgroup analysis at the 83rd American Diabetes Association (ADA) Scientific Sessions. Results from this primary prevention...

Kvika banki hf.: Correction: Notification regarding execution of buyback programme

Written by Customer Service on June 24, 2023. Posted in Public Companies.

On Friday 23 June 2023 Kvika announced that on 21 June 2023 the board of directors of Kvika decided to establish a buyback programme. However, the decision took place on 23 June 2023. The revised announcement is as follows: At the Annual General Meeting of Kvika banki hf. (“Kvika” or the “bank”) on 30 March 2023, the shareholders approved to authorise the board of directors to buy up to 10% of issued shares in the bank, to among other things enable the board of directors to carry out a formal buyback programme. On the basis of that approval, the board of directors of Kvika decided on 23 June 2023 to exercise a part of that authorisation and establish a buyback programme to carry out the purchase of shares for total consideration amount of ISK 1,000,000,000 but for no higher nominal amount than 60,000,000 shares, for the purpose of reducing...

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions

Written by Customer Service on June 24, 2023. Posted in Public Companies.

Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean of 4.2% from baseline (4.8% placebo-corrected) within one week following a single dose of ZP8396 and were well-sustained over six weeks of observation In development as an alternative non-incretin peptide therapy for the potential management of overweight and obesity A 16-week multiple ascending dose (MAD) study of ZP8396 has been initiated Copenhagen, Denmark, June 24, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that results from a Phase 1a clinical trial of ZP8396, the company’s long-acting amylin analog,...

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

Written by Customer Service on June 24, 2023. Posted in Public Companies.

– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals or immunomodulators alone – – Preclinical data suggest the potential of VIR-2218 and VIR-3434 as treatment for the chronic suppression of hepatitis D virus infection – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B and D virus (HBV and HDV) portfolio that were presented at the EASL™ (European Association for the Study of the Liver) Congress. Data presented in a late-breaker oral presentation from a Phase 2 clinical trial demonstrated that when...

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

Written by Customer Service on June 24, 2023. Posted in Public Companies.

– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the previously reported positive data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) were published online in Nature Medicine. As previously announced, ENTRIGUE met its primary endpoint of demonstrating statistically significant reductions in median triglycerides (TGs) from baseline...

Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

Written by Customer Service on June 24, 2023. Posted in Public Companies.

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in significant benefit across several key sub populations of NASH patients, and that adding pegozafermin to patients taking GLP-1 therapies improved key NASH measures – – Discussions with regulatory agencies regarding advancement into Phase 3 trials in NASH planned for the second half of 2023 – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from the Phase 2b ENLIVEN trial evaluating...

L’Institut Polytechnique, l’Agence de l’Innovation de Défense, Dassault Aviation, Dassault Systèmes, Naval Group et Nexter, annoncent la création d’une Chaire d’Enseignement et de Recherche dédiée à l’architecture des systèmes complexes

Written by Customer Service on June 24, 2023. Posted in Public Companies.

COMMUNIQUÉ DE PRESSE – 23 JUIN 2023 L’Institut Polytechnique de Paris (IP Paris), l’Agence de l’Innovation de Défense (AID), Dassault Aviation, Dassault Systèmes, Naval Group et Nexter, société de KNDS, annoncent la création d’une Chaire d’Enseignement et de Recherche dédiée à l’architecture des systèmes complexes Jeudi 22 juin 2023, au Salon du Bourget, a été officialisée la création d’une chaire d’enseignement et de recherche à l’Institut Polytechnique de Paris (IP Paris) sur l’architecture des systèmes complexes, en présence de Sébastien Lecornu, ministre des Armées, et d’Emmanuel Chiva, Délégué général pour l’armement. Dassault Aviation, Dassault Systèmes, Naval Group, Nexter, société de KNDS, et l’Agence de l’Innovation Défense (AID) sont les mécènes et partenaires de cette chaire qui ambitionne de développer l’enseignement et la...

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Written by Customer Service on June 24, 2023. Posted in Public Companies.

Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the abstract “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated With Responses in Adiponectin Levels” has been selected for poster presentation during the American Diabetes Association’s 83rd Scientific Sessions taking place on June 23-26, 202 in San Diego, United States. Adiponectin plays a critical role in energy homeostatis by regulating insulin sensitivity, lipid metabolism and control of glycemia. In addition adiponectin...

Day: June 24, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice